2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4270 Conditional long-term survival after adult umbilical cord blood transplantation: A 1-year landmark analysis

Amir Reza Akbari, MBCHB, Matthew Braun2, Nelson Chao, MD3, Mitchell Horwitz I, MD4, Anthony Sung, MD5
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 University of Kansas Medical Center, Kansas City, Kansas, United States
3 Duke University School of Medicine, Durham, North Carolina, United States
4 Duke University School of Medicine, Durham, North Carolina, United States
5 University of Kansas Medical Center, Kansas City, Kansas, United States

Background: Umbilical cord blood (UCB) is an established alternative graft source for allogeneic hematopoietic cell transplantation (HCT), but its use in adults is limited by substantial early morbidity and mortality. Survival estimates measured from transplantation may obscure prognosis among patients who survive the early high-risk period. We characterized early mortality, recorded cause-specific death, and conditional long-term survival after first allogeneic UCB transplantation for malignant hematologic disease.

Methods: We conducted a retrospective cohort study using Center for International Blood and Marrow Transplant Research data. Adults aged 18 years or older who underwent first allogeneic HCT with UCB for malignant hematologic disease between 1999 and 2024 were included. Overall survival (OS) beyond a prespecified 1-year landmark was estimated using the Kaplan-Meier method. Causes of death were summarized before and after the landmark. Cumulative incidence functions were estimated for death attributed to relapse-related causes, death attributed to non-relapse causes, and death with unknown or unavailable cause. Multivariable Cox regression, stratified by transplant era, evaluated predictors of post-landmark OS.

Results: Among 6,869 eligible adults, 3,245 (47.2%) died within the first year after transplantation and 3,624 (52.8%) survived to the 1-year landmark. At 1 year after HCT, the cumulative incidence of relapse-related death was 13.66% (95% CI, 12.88%-14.47%), compared with 29.46% (95% CI, 28.34%-30.62%) for death attributed to non-relapse causes. Among 1-year survivors, median OS from the landmark was 13.7 years (95% CI, 12.4 years to not reached). During post-landmark follow-up, 1,198 deaths occurred. Relapse or progression was the leading recorded cause of late death, accounting for 49.5% of deaths after the landmark. At 5 years after the landmark, the cumulative incidence was 17.37% (95% CI, 15.97%-18.88%) for relapse-related death and 16.23% (95% CI, 15.16%-17.39%) for death attributed to non-relapse causes. In multivariable analysis, older age (hazard ratio [HR] per year, 1.020; 95% CI, 1.015-1.025), progressive disease at HCT (HR, 1.579; 95% CI, 1.320-1.890), Karnofsky Performance Status ≤70 (HR, 1.243; 95% CI, 1.006-1.536), and nonmyeloablative conditioning (HR, 1.224; 95% CI, 1.063-1.410) were associated with worse post-landmark OS. OS from transplantation improved significantly across successive transplant eras (log-rank P<.0001).

Conclusions: Adult UCB transplantation is associated with substantial early mortality, predominantly from non-relapse causes. Among patients who survive to 1 year, long-term survival is durable. Relapse or progression becomes the leading individual cause of late death, although the cumulative incidences of relapse-related and non-relapse-cause death remain similar at 5 years after the landmark. These findings define a large multicenter benchmark for conditional survivorship after adult UCB transplantation and support a phase-based approach to care, emphasizing prevention of transplant-related mortality during the first year and increasing attention to relapse surveillance and prevention during long-term follow-up.

Amir Reza Akbari, MBCHB: No relevant conflicts of interest to declare.